Tiziana Life Sciences expands Phase 2 intranasal foralumab trial with dosing

Tiziana Life Sciences (TLSA) announced that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis. This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women’s Hospital, and the University of Massachusetts. The Phase 2 trial aims to evaluate the safety and efficacy of Tiziana’s innovative therapies in treating multiple sclerosis, a chronic autoimmune disease affecting the central nervous system. The Phase 2 trial is designed to build on preclinical data and initial clinical observations. Following the completion of the blinded phase, all participants-including those who initially received placebo-will have the opportunity to receive intranasal foralumab during a six-month open-label extension phase. The OLE is designed to assess long-term safety and sustained benefit of foralumab in the na-SPMS patient population.